Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.47 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP7 | P09237 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 5/20 | 0.42 |
| ▸ | ACE | P12821 | 4/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cpi 613 SCHEMBL1062218 | 0.92 | CYP2C19 (0.59) | CYP2C19PTGER1PTGER4PTGER3PTGER2 | |
| Cpi 613 SCHEMBL13333201 | 0.92 | CYP2C19 (0.59) | CYP2C19PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL17381514 | 0.91 | CYP2C19 (0.58) | CYP2C19PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL22299081 | 0.91 | CYP2C19 (0.58) | CYP2C19PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL10307764 | 0.86 | CYP2C19 (0.47) | CYP2C19PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL10307784 | 0.86 | CYP2C19 (0.44) | CYP2C19PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL16375392 | 0.84 | CYP1A2 (0.50) | CYP2C19PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL10307786 | 0.84 | CYP1A2 (0.52) | CYP2C19FFAR1 | |
| SCHEMBL20395792 | 0.84 | CYP2C19 (0.63) | CYP2C19PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL10307777 | 0.84 | CYP2C19 (0.52) | CYP2C19PTGER1PTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220184212-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | RAFAEL PHARMACEUTICALS INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-11065335-B2 | Methods of treating leukemia using compositions containing bis(benzylthio)octanoic acid and ion pairs thereof | RAFAEL PHARMACEUTICALS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-10391177-B2 | Methods for treating cancer using 6,8-bis (benzylthio) octanonic acid | RAFAEL PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190015512-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | CORNERSTONE PHARMACEUTICALS, INC. | 2019-01-17 | — | — | US | disclosed |
| US-20180104341-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | RAFAEL PHARMACEUTICALS, INC. | 2018-04-19 | — | — | US | disclosed |
| US-20180104341-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | RAFAEL PHARMACEUTICALS, INC. | 2018-04-19 | — | — | US | disclosed |
| US-9872845-B2 | Methods of treating myeloma and lymphoma using compositions containing an ion pair of a lipoic acid derivative | RAFAEL PHARMACEUTICALS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9872845-B2 | Methods of treating myeloma and lymphoma using compositions containing an ion pair of a lipoic acid derivative | RAFAEL PHARMACEUTICALS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9839691-B2 | Methods of treating pancreatic and ovarian cancers using compositions containing an ion pair of a lipoic acid derivative | RAFAEL PHARMACEUTICALS, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839691-B2 | Methods of treating pancreatic and ovarian cancers using compositions containing an ion pair of a lipoic acid derivative | RAFAEL PHARMACEUTICALS, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20120178812-A1 | Pharmaceutical Formulations Containing Lipoic Acid Derivatives | RAFAEL PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| WO-2011050261-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | CORNERSTONE PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20100190858-A1 | Pharmaceutical Formulations Containing Lipoic Acid Derivatives | RAFAEL PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190858-A1 | Pharmaceutical Formulations Containing Lipoic Acid Derivatives | RAFAEL PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2008131117-A1 | LIPOIC ACID DERIVATIVES | CORNERSTONE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008131114-A2 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | CORNERSTONE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080262034-A1 | selectively kill tumor cells by altering cancer cell metabolism and signal transduction pathways linked to the Warburg Effect; | CORNERSTONE PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080262034-A1 | selectively kill tumor cells by altering cancer cell metabolism and signal transduction pathways linked to the Warburg Effect; | CORNERSTONE PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080262077-A1 | formulations containing lipoic acid derivatives are made. | CORNERSTONE PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080262077-A1 | formulations containing lipoic acid derivatives are made. | CORNERSTONE PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184212-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | SLC25A1, SLC25A21, SLC25A11 | CYP2C19 500/4885PTGER1 1759/4885PTGER4 2343/4885 |
| US-10391177-B2 | Methods for treating cancer using 6,8-bis (benzylthio) octanonic acid | ALOX15B, ALOX5, SLC25A21 | CYP2C19 765/4885PTGER1 924/4885PTGER4 1845/4885 |
| US-20180104341-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | SLC25A1, SLC25A21, SLC25A11 | CYP2C19 500/4885PTGER1 1759/4885PTGER4 2343/4885 |
| US-20100190858-A1 | Pharmaceutical Formulations Containing Lipoic Acid Derivatives | SLC25A1, SLC25A21, SLC25A11 | CYP2C19 500/4885PTGER1 1759/4885PTGER4 2343/4885 |
| US-11065335-B2 | Methods of treating leukemia using compositions containing bis(benzylthio)octanoic acid and ion pairs thereof | MCL1, ALOX15, SLC10A6 | CYP2C19 1513/4885PTGER1 1218/4885PTGER4 2769/4885 |
| US-20120178812-A1 | Pharmaceutical Formulations Containing Lipoic Acid Derivatives | LIPA, LIPC, TTPA | CYP2C19 295/4885PTGER1 1941/4885PTGER4 2228/4885 |
| US-20080262034-A1 | selectively kill tumor cells by altering cancer cell metabolism and signal transduction pathways linked to the Warburg Effect; | DLD, SLC25A1, PDK2 | CYP2C19 3913/4885PTGER1 1489/4885PTGER4 2570/4885 |
| US-20190015512-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES | SLC25A1, SLC25A21, SLC25A11 | CYP2C19 500/4885PTGER1 1759/4885PTGER4 2343/4885 |
| US-20080262077-A1 | formulations containing lipoic acid derivatives are made. | TTPA, LIPA, LIPC | CYP2C19 273/4885PTGER1 1623/4885PTGER4 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.